Company
Legacy
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
16
15 still marketed
Novel approvals
10
Approvals since 2021
0
Originals and new uses
Phase 3 trials
1
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Esbriet approved OrphanJan 11, 2017
- Naftin new use Nov 10, 2016
- Esbriet approved NovelBreakthrough therapyPriority reviewOrphanOct 15, 2014
- Naftin new use Oct 10, 2014
- Naftin new use Oct 10, 2014
- Brisdelle approved Jun 28, 2013
- Naftin approved Jun 27, 2013
- Naftin new use Jan 13, 2012
- Lotronex new use Apr 1, 2008
- Lotronex new use Jan 31, 2005
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (15)
Newest FDA action first.
- Brisdelle Paroxetine Mesylate · 2013
- Zanaflex Tizanidine Hydrochloride · 1996
- Zanaflex Tizanidine Hydrochloride · 2002
- Imuran Azathioprine · 1968
- Lotronex Alosetron Hydrochloride · 2000
- Betapace Sotalol Hydrochloride · 1992
- Esbriet Pirfenidone · 2014
- Esbriet Pirfenidone · 2017
- Naftin Naftifine Hydrochloride · 2013
- Ethyol Amifostine · 1995
- Naftin Naftifine Hydrochloride · 1988
- Motofen Half-Strength Atropine Sulfate, Difenoxin Hydrochloride · 1978
- Ridaura Auranofin · 1985
- Betapace Af Sotalol Hydrochloride · 2000
- Cloderm Clocortolone Pivalate · 1977
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.